New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer
- 9 July 2024
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1879 (5) , 189152
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- PROTACs: Novel tools for improving immunotherapy in cancerCancer Letters, 2023
- Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunityBiomaterials, 2022
- Design, synthesis and biological evaluation of new dihydropyridine derivatives as PD-L1 degraders for enhancing antitumor immunityBioorganic Chemistry, 2022
- CMTM6 as a master regulator of PD-L1Cancer Immunology, Immunotherapy, 2022
- LYTACs: An Emerging Tool for the Degradation of Non‐Cytosolic ProteinsChemMedChem, 2021
- Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCCHepatology, 2021
- Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTORActa Pharmaceutica Sinica B, 2021
- Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5Acta Pharmaceutica Sinica B, 2020
- Ubiquitin–proteasome system (UPS) as a target for anticancer treatmentArchives of Pharmacal Research, 2020
- Homogeneous, Low‐volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD‐L1 for Cancer Diagnosis and Immunotherapy Response PredictionAngewandte Chemie International Edition, 2020